The DOI matches its Crossref record; 25 of the 27 references it cites were found in a registry or an index.
Effects of Smoking on the Pharmacokinetics of Erlotinib
Abstract
Purpose: To compare the pharmacokinetic variables of erlotinib in current smokers with nonsmokers after receiving a single oral 150 or 300 mg dose of erlotinib. Experimental Design: This was a single-center, open-label pharmacokinetic study in healthy male subjects. Subjects were enrolled into two treatment cohorts based on smoking status (current smokers and nonsmokers). The pharmacokinetic profile for erlotinib and its metabolite, OSI-420, was determined for each subject following each treatment. Results: Current smokers achieved significantly less erlotinib exposure following a single 150 or 300 mg dose than nonsmokers. Following the 150 mg dose, the geometric mean erlotinib AUC0-∞ in smokers was 2.8-fold lower than in nonsmokers and similar to that of nonsmokers at the 300 mg dose. Cmax in smokers was two-thirds of that in nonsmokers, and C24h in smokers was 8.3-fold lower than in nonsmokers. The median C24h of smokers at the 300 mg dose was slightly less than the C24h of smokers at the 150 mg dose. The median Cmax was greater in smokers at the 300 mg dose than in nonsmokers at the 150 mg dose. Conclusion: This study confirms that the pharmacokinetics of erlotinib is different in current smokers and nonsmokers. The observation that AUC0-∞ and C24h were significantly decreased in smokers compared with nonsmokers, and a smaller decrease in Cmax was observed, is consistent with increased metabolic clearance of erlotinib in current smokers.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This persistence in post-diagnosis smoking occurs in spite of the serious medical outcomes, including poorer treatment efficacy (e.g., lower response to radiation and chemotherapy for cancer treatment),7–10”
From Efficacy of smartphone applications to help cancer patients quit smoking: Protocol of the Quit2Heal randomized controlled trial (2023) · cites this paper as [9]
Citations
Cites
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citationBindingDB (2025) · PubMed · doi:10.7270/q2dr317m · Cited by 843
Drug Interactions with Tobacco Smoking: An Update
Zevin, S., & Benowitz, N. L. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936060-00004 · Cited by 692
Shepherd, F. A., Pereira, J. R., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Bezjak, A., Tu, D., Santabarbara, P., & Seymour, L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.7022 · Cited by 281
Smoking in Patients Receiving Psychotropic Medications: A Pharmacokinetic Perspective
Desai, H. D., Seabolt, J., & Jann, M. W. (2001) · CNS Drugs · doi:10.2165/00023210-200115060-00005 · Cited by 253
Effect of smoking on theophylline disposition
Hunt, S. N., Jusko, W. J., & Yurchak, A. M. (1976) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1976195part1546 · Cited by 226
Ling, J., Johnson, K. A., Miao, Z., Rakhit, A., Pantze, M. P., Hamilton, M., Lum, B. L., & Prakash, C. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007765 · Cited by 223
Self-citationConard, G. J., & Ober, R. E. (1984) · The American Journal of Cardiology · doi:10.1016/0002-9149(84)90501-0 · Cited by 203
the Boston Collaborative Drug Surveillance Program, B. U. M. C. (1973) · New England Journal of Medicine · doi:10.1056/nejm197302082880602 · Cited by 196
The human drug metabolizing cytochromes P450
Wrighton, S. A., VandenBranden, M., & Ring, B. J. (1996) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf02353474 · Cited by 164
Research works printed but not linked: 2
- Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. N Engl J Med 2005;353:123–32. · doi:10.1200/jco.2004.22.90140.7022 · Paper page
- Hamilton M, Wolf JL, Zborowski D, et al. Tarceva™ (erlotinib) exposure/effects (EE) analysis from a phase III study in advanced NSCLC: effect of smoking on the PK of erlotinib [abstract 6165]. Proc Am Assoc Cancer Res 2005;46:1451.
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Gatzemeier, U., Pluzanska, A., Szczesna, A., Kaukel, E., Roubec, J., De Rosa, F., Milanowski, J., Karnicka-Mlodkowski, H., Pesek, M., Serwatowski, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1474 · Cited by 881
Acquired resistance to TKIs in solid tumours: learning from lung cancer
Camidge, D. R., Pao, W., & Sequist, L. V. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.104 · Cited by 862
Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
Westover, D., Zugazagoitia, J., Cho, B. C., Lovly, C. M., & Paz-Ares, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx703 · Cited by 766
Benowitz, N. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.3 · Cited by 517
Metadata
- Authors
- Hamilton, M., Wolf, J. L., Rusk, J., Beard, S. E., Clark, G. M., Witt, K., & Cagnoni, P. J.
- Affiliations
- Authors' Affiliation: OSI Pharmaceuticals, Inc., Boulder, Colorado
- Venue
- Clinical Cancer Research
- Published
- 2006-04-01
- Volume
- 12
- Issue
- 7
- Pages
- 2166-2171
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2159023488
- Cited by
- 312
- References
- 27
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 5 · 2023: 4 · 2022: 9 · 2021: 10 · 2020: 15 · 2019: 16 · 2018: 17 · 2017: 12 · 2016: 16 · 2015: 24 · 2014: 22 · 2013: 27 · 2012: 18
- FWCI
- 16.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- erlotinib, smoking, pharmacokinetics, drug metabolism, metabolic clearance, smokers versus non-smokers, AUC, Cmax, dose comparison
- MeSH terms
- Erlotinib Hydrochloride, Adult, Dose-Response Relationship, Drug, Drug Administration Schedule, Humans, Male, Middle Aged, Quinazolines, Reference Values, Safety, Smoking, Time Factors, Cohort Studies, Molecular Structure, Cross-Over Studies, Area Under Curve
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Smoking on the Pharmacokinetics of Erlotinib. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-2235
- The paper
- Hamilton, M., Wolf, J. L., Rusk, J., Beard, S. E., Clark, G. M., Witt, K., & Cagnoni, P. J. (2006). Effects of Smoking on the Pharmacokinetics of Erlotinib. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-2235
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.